Fear of Mastectomy Associated with Delayed Breast Cancer Presentation Among Ghanaian Women.
CONCLUSION: Despite current efforts to increase breast cancer awareness, the fear of mastectomy remains one of the main reasons for delayed presentation. Successful breast cancer education programs will need to be framed within the broader sociocultural dimensions of femininity that address some of the stigma associated with mastectomy reported in the Ghanaian context. IMPLICATIONS FOR PRACTICE: Most women in Ghana present with advanced-stage disease. The aim of this study was to characterize sociocultural factors associated with delayed presentation. Although several quantitative studies have been conducted on delays...
Source: The Oncologist - June 29, 2018 Category: Cancer & Oncology Authors: Martei YM, Vanderpuye V, Jones BA Tags: Oncologist Source Type: research
Developing a Roadmap for Interventional Oncology.
This report focuses on current interventional procedures and techniques with a look toward future improvements that will improve cancer care and patient outcomes. PMID: 29959284 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - June 29, 2018 Category: Cancer & Oncology Authors: Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R Tags: Oncologist Source Type: research
Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial.
CONCLUSION: Training medical oncologists in SDM about palliative systemic treatment improves their performance in simulated consultations. The next step is to examine the effect of such training on SDM in clinical practice and on patient outcomes. IMPLICATIONS FOR PRACTICE: Systemic treatment for advanced cancer offers uncertain and sometimes limited benefit, while the burden can be high. Hence, applying the premises of shared decision-making (SDM) is recommended. SDM is increasingly advocated based on the ethical imperative to provide patient-centered care and the increasing evidence for beneficial patient outcomes. ...
Source: The Oncologist - June 29, 2018 Category: Cancer & Oncology Authors: Henselmans I, van Laarhoven HWM, de Haes HCJM, Tokat M, Engelhardt EG, van Maarschalkerweerd PEA, Kunneman M, Ottevanger PB, Dohmen SE, Creemers GJ, Sommeijer DW, de Vos FYFL, Smets EMA Tags: Oncologist Source Type: research
Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.
CONCLUSION: This study described for the first time objective cognitive changes before to after treatment of older adults with EBC immediately after the end of adjuvant treatment. A longer-term remote follow-up of adjuvant treatment is needed to better understand the cognitive trajectories of older patients with EBC. The Oncologist IMPLICATIONS FOR PRACTICE: After the end of adjuvant treatment, 31% of older adults with early-stage breast cancer without initial objective cognitive impairment developed impairment, and 6% experienced accelerated cognitive decline. Initial cognitive functioning should be included in the balanc...
Source: The Oncologist - June 22, 2018 Category: Cancer & Oncology Authors: Lange M, Heutte N, Noal S, Rigal O, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Leconte A, Veyret C, Barthélémy P, Longato N, Tron L, Castel H, Eustache F, Giffard B, Joly F Tags: Oncologist Source Type: research
Barriers and Facilitators to Cervical Cancer Screening, Diagnosis, Follow-Up Care and Treatment: Perspectives of Human Immunodeficiency Virus-Positive Women and Health Care Practitioners in Tanzania.
CONCLUSION: Given the fear, stigma, misinformation, and lack of resources surrounding cervical cancer, it is not surprising that patient navigation would be welcomed by patients and providers. The Oncologist IMPLICATIONS FOR PRACTICE: This article identifies specific barriers to cervical cancer screening and treatment from the perspectives of both clinicians and patients in Tanzania and describes the acceptability of the concept of patient navigation. PMID: 29934410 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - June 22, 2018 Category: Cancer & Oncology Authors: Bateman LB, Blakemore S, Koneru A, Mtesigwa T, McCree R, Lisovicz NF, Aris EA, Yuma S, Mwaiselage JD, Jolly PE Tags: Oncologist Source Type: research
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
CONCLUSION: Objective response rate and progression-free survival were significantly better in the irAE than in the non-irAE group in patients with advanced NSCLC treated with nivolumab monotherapy. The development of irAEs was associated with clinical efficacy, and the presence of pre-existing antithyroid antibody might be correlated with treatment response to nivolumab monotherapy. IMPLICATIONS FOR PRACTICE: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study evaluted whether the development of irAEs correlates with treatment response in advanced non-small-cell lung c...
Source: The Oncologist - June 22, 2018 Category: Cancer & Oncology Authors: Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y Tags: Oncologist Source Type: research
Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Abstract There is growing interest in the endocrine treatment (ET) of premenopausal women with hormone receptor positive (HR+) metastatic breast cancer (MBC). This review summarizes available data on endocrine therapy for this patient subset and aims to define the most appropriate treatment approach. The combination of luteinizing hormone-releasing hormone (LHRH) agonists plus tamoxifen seems effective and safe and is considered as being superior to either approach alone; still, single-agent therapy remains an acceptable treatment option. Due to their mechanism of action, aromatase inhibitors alone are not suitabl...
Source: The Oncologist - June 22, 2018 Category: Cancer & Oncology Authors: Tancredi R, Furlanetto J, Loibl S Tags: Oncologist Source Type: research
Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).
CONCLUSION: BM of sarcomas are rare and associated with a dismal outcome. Multidisciplinary management with chemotherapy, radiation therapy, and surgery is associated with a better survival. The Oncologist IMPLICATIONS FOR PRACTICE: The incidence of brain and meningeal metastasis in bone and soft tissue sarcomas is estimated between 1% and 8%. Published data are derived from small retrospective case series, often in the pediatric population. A prognostic index is important to guide both clinical decision-making and outcomes research, but one such is lacking for adult sarcoma patients with brain metastases. The current stud...
Source: The Oncologist - June 22, 2018 Category: Cancer & Oncology Authors: Chaigneau L, Patrikidou A, Ray-Coquard I, Valentin T, Linassier C, Bay JO, Moureau Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Laigre M, Guillemet C, Salas S, Hugli A, Domont J, Sunyach MP, Lecesne A, Blay JY, Nerich V, Isambert N Tags: Oncologist Source Type: research
Multidisciplinary Management of Breast Cancer During Pregnancy
(Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Shlomit Strulov Shachar, Kristalyn Gallagher, Kandace McGuire, Timothy M. Zagar, Aimee Faso, Hyman B. Muss, Raeshell Sweeting, Carey K. Anders Tags: Erratum Source Type: research
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
AbstractOn June 22, 2017, the Food and Drug Administration expanded indications for dabrafenib and trametinib to include treatment of patients with metastatic non‐small cell lung cancer (NSCLC) harboring BRAF V600E mutations. Approval was based on results from an international, multicenter, multicohort, noncomparative, open‐label trial, study BRF113928, which sequentially enrolled 93 patients who had received previous systemic treatment for advanced NSCLC (Cohort B, n = 57) or were treatment‐naïve (Cohort C, n = 36). All patients received dabrafenib 150 mg orally twice daily and trame...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Lauretta Odogwu, Luckson Mathieu, Gideon Blumenthal, Erin Larkins, Kirsten B. Goldberg, Norma Griffin, Karen Bijwaard, Eunice Y. Lee, Reena Philip, Xiaoping Jiang, Lisa Rodriguez, Amy E. McKee, Patricia Keegan, Richard Pazdur Tags: Lung Cancer, Regulatory Issues: FDA Source Type: research
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
AbstractOn February 22, 2017, the U.S. Food and Drug Administration (FDA) granted approval for the use of lenalidomide as maintenance therapy after autologous hematopoietic stem cell transplantation (auto‐HSCT) for patients with multiple myeloma. The approval was based on evidence from two randomized, blinded trials of maintenance lenalidomide versus placebo in patients with myeloma who had undergone auto‐HSCT along with a third trial of lenalidomide versus no therapy. Each of the trials demonstrated superior progression‐free survival for the patients treated with lenalidomide. The effect on overall survival was mixe...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Elizabeth Dianne Pulte, Andrew Dmytrijuk, Lei Nie, Kirsten B. Goldberg, Amy E. McKee, Ann T. Farrell, Richard Pazdur Tags: Myelomas, Regulatory Issues: FDA Source Type: research
Serious Illness Conversations: Paving the Road with Metaphors
This article provides guidance for preparing for such conversations, including examples of the use of metaphors to personalize and improve communication. (Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: David Hui, Donna S. Zhukovsky, Eduardo Bruera Tags: Symptom Management and Supportive Care Medical Ethics Source Type: research
Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B‐Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment
Conclusion.We observed that the ACA index could partially predict the clinical outcomes of elderly DLBCL patients in China. Based on this index, we proposed the IACA index as an effective tool for CGA in DLBCL.Implications for Practice.Diffuse large B‐cell lymphoma (DLBCL) is one of the most frequent types of malignant lymphoma in elderly people, and identifying patients suitable for curative therapy is critical in the improvement of clinical outcomes. Recently, some authors proposed the Age, Comorbidities, and Albumin (ACA) index. Combining the use of the instrumental activities of daily living (IADL) scale and the ACA ...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Hui Liu, Chun-Li Zhang, Ru Feng, Jiang-Tao Li, Yuan Tian, Ting Wang Tags: Lymphoma, Hematologic Malignancies, Chinese Edition Source Type: research
Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon‐α
We report the case of a patient with CML resistant to TKI and planned for an HSCT, in which treatment by TKI was replaced by interferon‐α before and during ovarian stimulation for fertility preservation. Successful ovarian stimulation was performed, allowing cryopreservation of nine zygotes. Hematopoietic stem cell transplantation was performed, and at present, 3 years later, the patient presents a sustained major molecular response. (Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Smaranda Gazdaru, Lucien Perey, Anne Rosselet, Patrice Mathevet, Yves Chalandon, Nicolas Vulliemoz Tags: Leukemias, Symptom Management and Supportive Care Brief Communications Source Type: research
Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension
AbstractBackground.The purpose of this study was to evaluate percutaneous transhepatic portal vein stenting (PVS) for palliation of refractory ascites and/or variceal bleeding caused by extrahepatic portomesenteric venous stenosis in patients with pancreaticobiliary cancer.Materials and Methods.A single‐institution, retrospective review of patients who underwent PVS between January 2007 and July 2015 was performed. A total of 38 patients were identified, of whom 28 met the inclusion criterion of PVS performed primarily for refractory ascites or variceal bleeding. In addition to technical success and overall survival, cli...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Rahul A. Sheth, Sharjeel H. Sabir, Philip Parmet, Roshon Amin, Joshua D. Kuban, Steven Y. Huang, Armeen Mahvash, David Fogelman, Milind Javle, Michael J. Wallace Tags: Symptom Management and Supportive Care Source Type: research
Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results‐Medicare Analysis
Conclusion.Treatment modality and survival differs by age and stage. Low socioeconomic status appears to be a major barrier to the receipt of PC therapy among Medicare patients.Implications for Practice.Elderly patients with cancer are under‐represented on clinical trials and usually have comorbid illnesses. The management of elderly patients with pancreatic cancer is unknown, with many retrospective experiences but low sample sizes. Using Surveillance, Epidemiology, and End Results‐Medicare linked data to analyze treatment patterns and survival of elderly patients with pancreatic cancer on a larger population scale, t...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Walid L. Shaib, Jeb S. Jones, Michael Goodman, Juan M. Sarmiento, Shishir K. Maithel, Kenneth Cardona, Suȷata Kane, Christina Wu, Olatunȷi B. Alese, Bassel F. El-Rayes Tags: Health Outcomes and Economics of Cancer Care, Gastrointestinal Cancer, Geriatric Oncology Source Type: research
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations
AbstractOlaparib is a poly(ADP‐ribose) polymerase enzyme inhibitor that is approved for use in patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have received three or more prior lines of chemotherapy for maintenance treatment of recurrent OC that is in response to platinum‐based chemotherapy regardless of BRCA mutation status and for human epidermal growth receptor factor 2‐negative metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Because olapari...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Kathleen N. Moore, Michael J. Birrer Tags: Review, Gynecologic Oncology Source Type: research
Refugees in Conflict: Creating a Bridge Between Traditional and Conventional Health Belief Models
This article presents the conclusions of a workshop attended by a group of clinicians and researchers affiliated with the Middle East Cancer Consortium, as well as four European‐based health‐related organizations. Workshop participants included leading clinicians and medical educators from the field of integrative medicine and supportive cancer care from Italy, Germany, Turkey, Israel, Palestine, Iran, Lebanon, Jordan, Egypt, and Sudan. The workshop illustrated the need for creating a dialogue between European health care professionals and the refugee population in order to overcome the communication barriers to create...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Eran Ben-Arye, Massimo Bonucci, Michel Daher, Reȷin Kebudi, Bashar Saad, Thomas Breitkreuz, Maryam Rassouli, Elio Rossi, Nahla Gafer, Omar Nimri, Mohamed Hablas, Gunver Sophia Kienle, Noah Samuels, Michael Silbermann Tags: Global Health and Cancer Source Type: research
Effect of Concomitant pH‐Elevating Medications with Pazopanib on Progression‐Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
Conclusion.Concomitant PPI or H2RA usage was not shown to be associated with a reduction in PFS or OS for patients receiving pazopanib for mRCC, with a similar toxicity profile in each group. Based on the results of this retrospective cohort study and the palliative nature of the treatment of patients with mRCC, clinicians should consider allowing patients to remain on concomitant pazopanib and acid‐reducing therapy.Implications for Practice.Pazopanib is a preferred category‐one first‐line treatment for predominant clear cell metastatic renal cell carcinoma (mRCC). However, because of an aging demographic, coupled wi...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Renee K. McAlister, Jonathan Aston, Megan Pollack, Liping Du, Tatsuki Koyama, David D. Chism Tags: Genitourinary Cancer Source Type: research
A Curative‐Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single‐Institutional Experience
Conclusion.Trimodality therapy produces sustainable long‐term survival in selected patients with metastatic CRC presenting with isolated retroperitoneal or mesenteric nodal relapse.Implications for Practice.This article reports a unique trimodality approach incorporating external beam radiotherapy with radiosensitizing chemotherapy, surgical resection, and intraoperative radiotherapy provides durable survival benefit with significant curative potential for patients with metastatic colorectal cancer who present with isolated abdominal nodal (mesenteric and/or retroperitoneal) recurrence. (Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Benny Johnson, Zhaohui Jin, Michael G. Haddock, Christopher L. Hallemeier, James A. Martenson, Rory L. Smoot, David W. Larson, Eric J. Dozois, David M. Nagorney, Axel Grothey Tags: Gastrointestinal Cancer Source Type: research
Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy
Conclusion.Patients without a decrease in Ki67 in residual tumors after NAC have poor prognosis. This warrants the introduction of new therapeutic strategies in this setting.Implications for Practice.This study evaluates the change in Ki67 percentage before and after neoadjuvant chemotherapy (NAC) and its relationship with survival outcomes in patients with breast cancer who did not achieve complete pathological response (pCR). These patients, a heterogeneous group with diverse prognoses that cannot be treated using a single algorithm, pose a challenge to clinicians. This study identified a subgroup of these patients with ...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Paula Cabrera-Galeana, Wendy Munoz-Montano, Fernando Lara-Medina, Alberto Alvarado-Miranda, Victor Perez-Sanchez, Cynthia Villarreal-Garza, R. Marisol Quintero, Fany Porras-Reyes, Enrique Bargallo-Rocha, Ignacio Del Carmen, Aleȷandro Mohar, Oscar A Tags: Precision Medicine, Breast Cancer Source Type: research
Emerging Perspectives on mTOR Inhibitor‐Associated Pneumonitis in Breast Cancer
This article provides an overview of mTOR inhibitor‐associated pneumonitis, with a focus on the detection, accurate diagnosis, and optimal management of this class‐related complication of mTOR inhibitor therapy.Implications for Practice.This article summarizes the pathogenesis, clinical presentation, incidence, detection, and optimal management of everolimus‐related noninfectious pneumonitis in breast cancer. In particular, this article provides a detailed overview of the important aspects of the detection, accurate diagnosis, and appropriate management of mammalian target of rapamycin inhibitor‐associated pneumoni...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Ricardo H. Alvarez, Rabih I. Bechara, Michael J. Naughton, Javier A. Adachi, James M. Reuben Tags: Symptom Management and Supportive Care, Breast Cancer Source Type: research
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Conclusion.OPB‐111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B‐cell lymphoma. Overall, modest efficacy was observed against unselected tumors. (Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M Tags: New Drug Development and Clinical Pharmacology, Chinese Edition, Clinical Trial Results Source Type: research
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
Conclusion.Selinexor demonstrated clinical activity and poor tolerability in mCRPC patients refractory to second‐line anti‐androgenic agents. (Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Xiao X. Wei, Adam P. Siegel, Rahul Aggarwal, Amy M. Lin, Terence W. Friedlander, Lawrence Fong, Won Kim, Mirela Louttit, Emily Chang, Li Zhang, Charles J. Ryan Tags: Prostate, Chinese Edition, Clinical Trial Results, Genitourinary Cancer Source Type: research
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer
Conclusion.There was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first‐line NS‐NSCLC. (Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Joachim von Pawel, David R. Spigel, Thomas Ervin, Gyorgy Losonczy, Fabrice Barlesi, Erzsebet Juhasz, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research
Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair‐Deficient Endometrial Cancer and a Germline BRCA1 Mutation
AbstractEndometrial cancer is the most common gynecologic malignancy in the U.S. and, although the majority of cases present at an early stage and can be treated with curative intent, those who present with advanced disease, or develop metastatic or recurrent disease, have a poorer prognosis. A subset of endometrial cancers exhibit mismatch repair (MMR) deficiency. It is now recognized that MMR‐deficient cancers are particularly susceptible to programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors, and in a landmark judgement in 2017, the U.S. Food and Drug Administration granted accele...
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Don S. Dizon, Dora Dias-Santagata, Amy Bregar, Laura Sullivan, Jennifer Filipi, Elizabeth DiTavi, Lucy Miller, Leif Ellisen, Michael Birrer, Marcela DelCarmen Tags: Gynecologic Oncology, Precision Medicine Precision Medicine Clinic: Molecular Tumor Board Source Type: research
Implementing Keytruda/Pembrolizumab Testing in Clinical Practice
(Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Dmitry Ratner, Jochen K. Lennerz Tags: Precision Medicine Commentaries Source Type: research
Fertility Preservation in Leukemia
(Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Zeev Blumenfeld Tags: Leukemias, Symptom Management and Supportive Care Commentaries Source Type: research
Can We Hang Our Hats on One Percent?
(Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Nathalie LeVasseur, Karen A. Gelmon Tags: Breast Cancer Commentaries Source Type: research
Looking Back, Looking Forward: The Ethical Framing of Complementary and Alternative Medicine in Oncology Over the Last 20 Years
(Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Brittany C. Kimball, Gail Geller, Rahma Warsame, Ashok Kumbamu, Aminah Jatoi, Barbara Koenig, Jon C. Tilburt Tags: Symptom Management and Supportive Care, Medical Ethics Commentaries Source Type: research
Canakinumab and Lung Cancer: Intriguing, but Is It Real?
(Source: The Oncologist)
Source: The Oncologist - June 19, 2018 Category: Cancer & Oncology Authors: Bruce A. Chabner, Christopher S. Nabel Tags: New Drug Development and Clinical Pharmacology Editorial Source Type: research
Pattern and Predictors of Outpatient Palliative Care Referral Among Thoracic Medical Oncologists.
CONCLUSION: The pattern of referral to outpatient palliative care varied widely among thoracic oncologists. Younger oncologists were not only referring a higher proportion of patients, but also referring patients earlier in the disease trajectory. IMPLICATIONS FOR PRACTICE: This retrospective cohort study found that younger thoracic medical oncologists were significantly more likely to refer patients to outpatient palliative care and to do so earlier in the disease trajectory compared with older oncologists, even after adjusting for other known predictors such as patient demographics. The findings highlight the role o...
Source: The Oncologist - June 12, 2018 Category: Cancer & Oncology Authors: Hui D, Kilgore K, Park M, Liu D, Kim YJ, Park JC, Fossella F, Bruera E Tags: Oncologist Source Type: research
Pertuzumab: Getting the Balance Right.
PMID: 29895630 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - June 12, 2018 Category: Cancer & Oncology Authors: Zekri J, Abdelghany EM, Abed-Alsater F Tags: Oncologist Source Type: research
Tumor Lysis Syndrome in the 21st Century: To Recreate Risk Factors and Prognosis?
PMID: 29895631 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - June 12, 2018 Category: Cancer & Oncology Authors: Vincent F, Darmon M Tags: Oncologist Source Type: research
Frontline Treatment for Older Patients with Mantle Cell Lymphoma.
Abstract The natural history of mantle cell lymphoma (MCL) undergoing chemotherapy is a cyclical pattern of remission followed by recurrence of disease due to acquired chemotherapy resistance. The median age of the occurrence of MCL is 65 years, so half of the newly diagnosed MCL patients are considered "elderly." The tolerance to long-term chemotherapy in elderly patients is decreased; hence, the response to frontline therapy used is of paramount importance. We hope that our review may guide clinicians in treating such populations in a more personalized and evidence-based manner.In the older patients wi...
Source: The Oncologist - June 12, 2018 Category: Cancer & Oncology Authors: Ye H, Desai A, Zeng D, Romaguera J, Wang ML Tags: Oncologist Source Type: research
Reflections on the Boston Marathon from a Breast Cancer Oncologist (or, Why I Just Don't Quit).
PMID: 29895633 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - June 12, 2018 Category: Cancer & Oncology Authors: Comander AH Tags: Oncologist Source Type: research
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Abstract Choosing the optimal therapy for a patient's cancer has long been based on whether the cancer demonstrates a predictive marker of efficacy. The U.S. Food and Drug Administration (FDA) has now approved use of a targeted therapy based solely on tumor molecular markers (pembrolizumab for tumors with deficient mismatch repair [MMR] and high microsatellite instability [MSI]) and approved another therapy based solely on a germline mutation as the predictive marker of benefit (olaparib for BRCA carriers with ovarian or breast cancer) [New Engl J Med 2017;377:1409-1412, N Engl J Med 2012;366:1382-1392, N Eng J Me...
Source: The Oncologist - June 4, 2018 Category: Cancer & Oncology Authors: Sorscher S Tags: Oncologist Source Type: research
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Abstract BACKGROUND: Gastroesophageal cancers are often grouped together even though cancers that originate in the esophagus often exhibit different histological features, geographical distribution, risk factors, and clinical characteristics than those originating in the stomach. Herein, we aimed to compare the molecular characteristics of three different gastroesophageal cancer types: esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), and gastric adenocarcinoma (GAC). SUBJECTS, MATERIALS, AND METHODS: In total, 3,342 gastroesophageal cancers were examined. Next-generation sequencing ...
Source: The Oncologist - June 4, 2018 Category: Cancer & Oncology Authors: Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM Tags: Oncologist Source Type: research
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Abstract Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) ...
Source: The Oncologist - June 4, 2018 Category: Cancer & Oncology Authors: Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL Tags: Oncologist Source Type: research
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
CONCLUSION: The dose escalation phase of this study was not completed, but the limited data obtained suggest that this combination may be too toxic when administered on this dosing schedule. The Oncologist 2018. PMID: 29853657 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 31, 2018 Category: Cancer & Oncology Authors: Meehan R, Kummar S, Do K, O'Sullivan Coyne G, Juwara L, Zlott J, Rubinstein L, Doroshow JH, Chen AP Tags: Oncologist Source Type: research
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
CONCLUSION: Ramucirumab-pembrolizumab showed limited clinical activity with infrequent grade 3-4 TRAEs in patients with biomarker-unselected progressive BTC. The Oncologist 2018. PMID: 29853658 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 31, 2018 Category: Cancer & Oncology Authors: Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I Tags: Oncologist Source Type: research
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Abstract Many human tumors are recognized by the adaptive immune system, but these spontaneous antitumor responses are typically inadequate to mediate regression. Blockade of immune regulatory "checkpoint" receptors such as cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death 1 can unleash antitumor immunity, resulting in tumor responses that can be durable. Alongside the enormous promise of immunotherapy for cancer, the immune dysregulation of checkpoint blockade has led to a plethora of new autoimmune adverse events. Hepatic toxicity occurs in 1%-17% of patients on immune checkpoint in...
Source: The Oncologist - May 31, 2018 Category: Cancer & Oncology Authors: Reynolds K, Thomas M, Dougan M Tags: Oncologist Source Type: research
E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
CONCLUSION: Motesanib (AMG 706) demonstrated a 4-month PFS that met the per-protocol definition of efficacy. Fatigue and hypertension were the most common toxicities, and few grade 3-4 toxicities were encountered. The progression-free survival of 8.7 months in all NETs merits further study. The Oncologist 2018. PMID: 29853660 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 31, 2018 Category: Cancer & Oncology Authors: Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Louis Hinshaw J, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A Tags: Oncologist Source Type: research
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study.
CONCLUSION: The everolimus-octreotide combination provided clinically relevant efficacy in nonfunctioning GI-NETs, similar to the results of RADIANT-2 in functioning setting. IMPLICATIONS FOR PRACTICE: The EVERLAR study reports prospective data of somatostatin analogue in combination with everolimus in nonfunctioning gastrointestinal neuroendocrine tumors suggesting meaningful activity and favorable toxicity profile that supports drug combination in this setting. PMID: 29794066 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 23, 2018 Category: Cancer & Oncology Authors: Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R, EVERLAR study investigators Tags: Oncologist Source Type: research
Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients.
CONCLUSION: PSG and PGI seem to be relevant for patients' assessment and decision-making process, translating in terms of therapeutic intervention. Some factors may be implicated in determining the individual target and clinical response. IMPLICATIONS FOR PRACTICE: Personalized symptom goals and global impression of change are relevant for patients' assessment and decision-making process, translating in terms of therapeutic intervention. Some factors may be implicated in determining the individual target and clinical response. PMID: 29769382 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 16, 2018 Category: Cancer & Oncology Authors: Mercadante S, Adile C, Lanzetta G, Mystakidou K, Maltoni M, Soares LG, De Santis S, Ferrera P, Valenti M, Rosati M, Rossi R, Cortegiani A, Masedu F, Marinangeli F, Aielli F Tags: Oncologist Source Type: research
Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
CONCLUSION: The incidence of TFTAs with ICI therapy was higher than previously reported. Patients with baseline TFTAs and/or who were receiving ipilimumab and nivolumab combination therapy had a higher incidence of TFTAs than patients receiving single-agent ICI therapy. We recommend more frequent evaluation of thyroid function in the first 8 weeks, especially in patients with baseline TFTAs. IMPLICATIONS FOR PRACTICE: Increased use of immune-checkpoint inhibitors in cancer treatment has highlighted the importance of monitoring for and treating immune-related adverse events. This study was conducted to assess the incid...
Source: The Oncologist - May 16, 2018 Category: Cancer & Oncology Authors: Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP Tags: Oncologist Source Type: research
Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources.
This article presents the principles of designing and conducting meta-research and proposes practical recommendations on how to perform and report this type of potentially very creative study. PMID: 29769384 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 16, 2018 Category: Cancer & Oncology Authors: Riechelmann RP, Péron J, Seruga B, Saad ED Tags: Oncologist Source Type: research
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
Abstract LESSON LEARNED: Panitumumab plus irinotecan is not active for the treatment of esophageal adenocarcinoma. BACKGROUND: Esophageal adenocarcinoma (EAC) is a lethal cancer with increasing incidence. Panitumumab (Pa) is a fully humanized IgG2 monoclonal antibody against human EGFR. Cetuximab (Cx) combined with irinotecan (Ir) is active for second-line treatment of colorectal cancer. This phase II study was designed to evaluate Pa plus Ir as second-line therapy for advanced EAC. METHODS: The primary endpoint was response rate (RR). Patients with one prior treatment were given Pa 9 mg/m2 on day 1 and ...
Source: The Oncologist - May 16, 2018 Category: Cancer & Oncology Authors: Yoon H, Choudhary A, Kosozi R, Bali GS, Zaidi A, Atasoy A, Forastiere AA, Gibson MK Tags: Oncologist Source Type: research
Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.
Abstract Globally, biosimilars are expected to have a key role in improving patient access to biological therapies and addressing concerns regarding the escalating cost of health care. Indeed, in Europe, increased use of biologics and reduced drug prices have been observed after the introduction of biosimilars. Recently, several monoclonal antibody biosimilars of anticancer therapies have been approved, and numerous others are in various stages of clinical development. Biosimilars are authorized via a regulatory pathway separate from that used for generic drugs; they are also regulated separately from novel biolog...
Source: The Oncologist - May 16, 2018 Category: Cancer & Oncology Authors: Cazap E, Jacobs I, McBride A, Popovian R, Sikora K Tags: Oncologist Source Type: research
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
This article summarizes the scientific review of the application leading to regulatory approval in the European Union. The full scientific assessment report and product information, including the Summary of Product Characteristics, are available on the European Medicines Agency website (http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid=).Implications for Practice.Farydak was approved in the European Union in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two p...
Source: The Oncologist - May 11, 2018 Category: Cancer & Oncology Authors: Kyriaki Tzogani, Paula van Hennik, Ita Walsh, Pieter De Graeff, Annika Folin, Jan Sȷoberg, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti Tags: Myelomas, Regulatory Issues: EMA Source Type: research